IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.64
+0.27 (+2.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.37
Open10.50
Bid0.00 x 2200
Ask0.00 x 800
Day's Range10.30 - 10.66
52 Week Range7.60 - 17.76
Volume717,141
Avg. Volume1,447,139
Market Cap1.656B
Beta (3Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-1.94
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.36
Trade prices are not sourced from all markets
  • Cambridge’s Ironwood Pharma moving HQ to downtown Boston
    American City Business Journals5 days ago

    Cambridge’s Ironwood Pharma moving HQ to downtown Boston

    The move comes after longtime Ironwood CEO Peter Hecht left the company to lead spinoff Cyclerion Therapeutics.

  • Business Wire5 days ago

    Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced that the company plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge, Massachusetts. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street. Ironwood anticipates the move to be completed in the fourth quarter of 2019, and expects to save more than $25 million in cash payments to its landlord over the following five years.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWDView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $1.20 billion over the last one-month into ETFs that hold IRWD are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
    Zacks13 days ago

    Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

    Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

  • Business Wire15 days ago

    Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced the initiation of patient dosing in a Phase II clinical trial evaluating MD-7246 in patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D). Data from the Phase II trial are expected in the second half of 2020. Ironwood and Allergan are evaluating MD-7246, an investigational new product, as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with certain GI diseases.

  • Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?
    Zacks17 days ago

    Why Is Ironwood (IRWD) Up 6.9% Since Last Earnings Report?

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Barrons.com24 days ago

    Sarissa Capital Is Drawn to Ironwood Pharmaceuticals

    On the same day, Marathon issued a letter to e.l.f.’s board that questioned moves by the company to “vary equity grant dates, earnings release dates, forward guidance, and fiscal year end” over the past three years. Marathon said the company acted in a “deliberate manner that consistently benefited [e.l.f.’s] executives” at the expense of shareholders. Marathon also stated that the best remedy for this situation would be to bring aboard additional, fully independent directors, including someone designated to the compensation committee.

  • Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
    Motley Foollast month

    Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today

    An SEC filing shows an activist investor is building a sizable position in the company.

  • 6 Positions the Vanguard Health Care Fund Continues to Increase
    GuruFocus.comlast month

    6 Positions the Vanguard Health Care Fund Continues to Increase

    CVS Health tops the list

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Ironwood Pharmaceuticals Inc Earnings Call

  • Business Wirelast month

    Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

    – IW-3718 Phase II data in patients with persistent GERD to be featured in oral presentation –

  • Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?
    Simply Wall St.last month

    Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors can approximate the average market return by buying an index fund. While individual st...

  • Business Wirelast month

    Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (IRWD) will present a corporate update at the 2019 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2019 at 8:00 a.m. Pacific Time at The Encore Hotel in Las Vegas. A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required.

  • Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
    Zacks2 months ago

    Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall

    Ironwood (IRWD) misses on both earnings and sales in the first quarter. The company completes its separation into two entities.

  • Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript

    IRWD earnings call for the period ending March 31, 2019.

  • Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

    Ironwood (IRWD) delivered earnings and revenue surprises of -62.50% and -17.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Ironwood: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 38 cents per share. Losses, adjusted for non-recurring costs and restructuring costs, came to 26 cents per share. The results missed Wall ...

  • Business Wire2 months ago

    Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

    – Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019 –

  • Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks2 months ago

    Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its first quarter 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 2, 2019. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 8429338. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • Business Wire2 months ago

    Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced an adjustment to the conversion rate applicable to its existing 2.25% Convertible Senior Notes due 2022, effective April 15, 2019. The adjustment was effected pursuant to the indenture, dated as of June 15, 2015, and as supplemented April 5, 2019, between Ironwood and U.S. Bank National Association, as trustee, pursuant to which the Convertible Notes were originally issued. In connection with the separation of Ironwood and Cyclerion Therapeutics, Inc. (Cyclerion) into two independent, publicly traded companies, on April 1, 2019, Ironwood distributed to its shareholders one share of Cyclerion common stock for every 10 shares of Ironwood common stock held as of the close of business on March 19, 2019, the record date for the distribution.

  • Will Ironwood Suffer From Dependence on Linzess' Progress?
    Zacks2 months ago

    Will Ironwood Suffer From Dependence on Linzess' Progress?

    Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.